Health Care · In Vitro & In Vivo Diagnostic Substances · Nasdaq · CIK 1870144 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.58Day +1.28%Mkt cap $5M1Y −59.2%Off 52W high −80.0%Vol (1Y) 148.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 938 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.2% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+0.90% |
| Top-10 13F concentration99.9% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$16,565 |
| Earnings (TTM)-$6.7M |
| ROE−78.6% |
| Net margin−43832.5% |
| Sales growth 3Y149.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−41.7% |
| 1Y−59.2% |
| 3Y−95.6% |
| Since incept. (ann.)−68.0% |
Total return through 2026-07-29 · series begins 2022-10-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)148.7% |
| Ann. volatility (3Y)184.6% |
| Sharpe (1Y)−0.02 |
| Sharpe (3Y)0.21 |
| Max drawdown (1Y)−79.1% |
| Max drawdown (3Y)−98.9% |
| Beta (3Y vs SPY)7.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| JANE STREET GROUP, LLC | 81,283 | $158,502 | 2.75% | new |
| HRT FINANCIAL LP | 62,482 | $121,000 | 2.11% | new |
| BlackRock, Inc. | 34,708 | $67,681 | 1.17% | −2.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 32,177 | $62,744 | 1.09% | +112.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 20,155 | $39,302 | 0.68% | new |
| RENAISSANCE TECHNOLOGIES LLC | 15,348 | $29,929 | 0.52% | new |
| Scientech Research LLC | 13,880 | $27,066 | 0.47% | new |
| UBS Group AG | 9,919 | $19,343 | 0.34% | +941.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.63 | — | $2,680 | +185.1% |
| 2025-12-31 | 2026-03-13 | — | — | $3,555 | −21.2% |
| 2025-09-30 | 2025-11-12 | −$0.98 | — | $2,855 | −56.6% |
| 2025-06-30 | 2025-08-14 | −$0.97 | — | $7,475 | −5.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable Segments 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
